Key Drivers
- Cash Flow Strength
- Quarterly Loss Swing
- Dividend Pressure
AIAI Summary
Pfizer is no longer just a post-COVID laggard: improving non-COVID growth, launch momentum, and strong free cash flow support the dividend, but the investment remains a hold until those gains clearly outpace the 2026–2028 patent cliff and recurring impairment/legal risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Flow Strength
- •Quarterly Loss Swing
- •Dividend Pressure
Pfizer remains cash-generative and profitable on a trailing annual basis, but the latest quarter swung to losses with elevated leverage and weak dividend coverage, making the shares only moderately attractive at current levels.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •$26.2 support
- •Near-term extension
PFE has been in a strong last month uptrend, rising from the mid-$24s to $26.79-$27.05, with $26.2 acting as support but the stock now looking extended near resistance after a sharp rally.
Rapid climb from the mid-$24s to $27.05 over the last month signals extension and profit-taking risk
Sentiment & News
Key News Insights:
- •Q2 Beat
- •Non-COVID Growth
- •Pipeline Upside
Pfizer is showing a turnaround as Q2 beats, higher 2026 guidance, and stronger non-COVID growth help offset COVID declines and patent-cliff pressure, with pipeline launches supporting sentiment.
The earnings surprise and raised outlook should support Pfizer shares near term, though legacy headwinds still cap the longer-term re-rating
Similar Companies in Healthcare
Other companies in the same sector with AI ratings